BioSpace News Archive

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced updated results from BRACELET-1, a randomized phase 2 trial in HR+/HER2- metastatic breast cancer, which include data featured in an oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, as well as additional new data and analyses.

Ginkgo Bioworks Holdings, Inc. announced today that management is scheduled to participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference, on June 12, 2023, at 4:40 p.m. PT.

Lucid Diagnostics Inc., a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary of PAVmed Inc., announced the launch of its first EsoGuard® #CheckYourFoodTube Mobile Test Unit serving patients and practices in the Greater Central Florida area.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jefferies 2023 Global Healthcare Conference in New York City on Friday, June 9, 2023.

Perimeter Medical Imaging AI, Inc. announced that Jeremy Sobotta has resigned as Chief Executive Officer of the Company, effective June 15, 2023 , for personal reasons.

Numinus Wellness Inc. is pleased to announce Cedar Clinical Research (CCR) is a top research site for MindMed’s Phase 2b study evaluating MM-120 (lysergide D-tartrate) for General Anxiety Disorder.

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today announced the appointment of Dr. Guillaume Dorothée, Ph.D., to Coya’s SAB, joining a roster of scientific luminaries.

Enrollment Completion Achieved in Less Than Six Months from Trial Commencement, Ahead of Original Timing Expectations.

AGC Biologics today announced AGCellerate, a new program designed to deliver effective IND-ready GMP material for biopharmaceutical developers.

AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced the presentation of final results from a Phase 2 study of posoleucel, an investigational, allogeneic, off-the-shelf, multi-virus-specific T cell (VST) therapy, being studied for the treatment of BK viremia in adult kidney transplant recipients.